Tenecteplase is a fibrin-specific plasminogen activator that has shown promising results in the treatment of acute ischemic stroke. Tenecteplase has been suggested to reduce door-to-needle time and to increase the rate of spontaneous recanalization. In February 2021, Mayo Clinic Health System switched to Tenecteplase as the standard thrombolytic therapy for acute ischemic stroke.

中文翻译：

---

从阿替普酶转向替奈普酶治疗急性缺血性中风-梅奥诊所经验。

替奈普酶是一种纤维蛋白特异性纤溶酶原激活剂，在治疗急性缺血性中风方面显示出良好的效果。建议使用替奈普酶来缩短入院至进针时间并提高自发再通率。2021年2月，梅奥诊所医疗系统改用替奈普酶作为急性缺血性中风的标准溶栓治疗。